Biomarker discovery in mass spectrometry-based urinary proteomics.
Biomarker discovery in mass spectrometry-based urinary proteomics.
复制标题
DOI：
10.1002/prca.201500102
复制
发表时间：
2016-04
期刊：
影响因子：
--
通讯作者：
Li L
中科院分区：
文献类型：
--
作者：
Thomas S;Hao L;Ricke WA;Li L
尿蛋白质组学已成为疾病生物标志物发现中最具吸引力的课题之一。基于质谱（MS）的蛋白质组学分析不断发展，已成为临床生物分析领域的重要工具。然而，只有少数蛋白质生物标志物已经进入验证和临床实践。生物标志物的发现受到许多临床和分析因素的挑战，包括但不限于尿液的复杂性和样品中内源性蛋白质的广泛动态范围。本文重点介绍了基于质谱的生物标志物发现过程中有前途的技术和策略，包括研究设计、样品制备、蛋白质定量、仪器平台和生物信息学。本文讨论了不同的蛋白质组学方法，并着重介绍了最大化尿蛋白质组学覆盖和标准化的进展。基于ms的尿蛋白质组学在未来的无创诊断分析中具有巨大的发展潜力，这需要分析科学家、系统生物学家和临床医生之间的合作努力。
Urinary proteomics has become one of the most attractive topics in disease biomarker discovery. Mass spectrometry (MS)-based proteomic analysis has advanced continuously and emerged as a prominent tool in the field of clinical bioanalysis. However, only few protein biomarkers have made their way to validation and clinical practice. Biomarker discovery is challenged by many clinical and analytical factors including, but not limited to, the complexity of urine and the wide dynamic range of endogenous proteins in the sample. This article highlights promising technologies and strategies in the MS-based biomarker discovery process, including study design, sample preparation, protein quantification, instrumental platforms, and bioinformatics. Different proteomics approaches are discussed, and progresses in maximizing urinary proteome coverage and standardization are emphasized in this review. MS-based urinary proteomics has great potential in the development of noninvasive diagnostic assays in the future, which will require collaborative efforts between analytical scientists, systems biologists, and clinicians.